Ette E I
Office of Clinical Pharmacology & Biopharmaceutics, Food and Drug Administration, Rockville, Maryland 20857, USA.
J Clin Pharmacol. 1997 Jun;37(6):486-95. doi: 10.1002/j.1552-4604.1997.tb04326.x.
This study aimed to determine the stability (in terms of covariate selection) of a population pharmacokinetic model and evaluate its performance in the absence of a test data set. Data from 88 full-term infants, 11 of whom were human immunodeficiency virus (HIV)-seropositive, taking an antiinfective agent were analyzed using exploratory data analysis methods and the nonlinear mixed-effects modeling (NONMEM) program to obtain the final population pharmacokinetic model. The stability of the population pharmacokinetic model was tested using the nonparametric bootstrap approach in four steps: 1) with the base pharmacokinetic model, 100 bootstrap replicates of the original data were generated by sampling with replacement; 2) ascertainment that each bootstrap data replicate was described by the basic structural model using the NONMEM objective function; 3) generalized additive modeling (GAM) applied to empiric Bayesian estimates for covariate selection at alpha = 0.05 and a frequency (f) cutoff value of 0.50; and 4) NONMEM population model building using covariates selected in the third step with alpha = 0.005. Performance of the population pharmacokinetic model was evaluated using 200 additional bootstrap replicates of the data by fitting the model obtained in step 4 to them. Parameters obtained were compared with those obtained in the model stability step, and improved prediction error, a measure of predictive accuracy as an index of internal validation, was computed. The reciprocal of serum creatinine (RSC; f = 0.73) and HIV (f = 0.70) were selected by GAM as predictors of clearance (Cl). The population pharmacokinetic model obtained without the determination of model stability included RSC as a predictor of Cl, but the final model from the model stability step included both HIV and RSC as predictors of Cl. Final population pharmacokinetic parameters were obtained with this model fitted to the original data; however, the 95% confidence interval on the HIV status regression coefficient included zero, indicating no significance. The mean parameter estimates obtained with the additional 200 bootstrap replicates of data were within 15% of those obtained with the final model at the regression stability step. Bootstrap resampling procedure is useful for evaluating the stability and performance of a population model by repeatedly fitting it to the bootstrap samples when there is no test data set.
本研究旨在确定群体药代动力学模型的稳定性(在协变量选择方面),并在没有测试数据集的情况下评估其性能。使用探索性数据分析方法和非线性混合效应建模(NONMEM)程序分析了88名足月儿的数据,其中11名人类免疫缺陷病毒(HIV)血清学阳性,正在服用抗感染药物,以获得最终的群体药代动力学模型。群体药代动力学模型的稳定性通过非参数自助法分四步进行测试:1)对于基础药代动力学模型,通过有放回抽样生成100个原始数据的自助重复样本;2)使用NONMEM目标函数确定每个自助数据重复样本是否由基本结构模型描述;3)在α = 0.05和频率(f)截止值为0.50的情况下,将广义相加模型(GAM)应用于经验贝叶斯估计以进行协变量选择;4)使用第三步中选择的协变量(α = 0.005)构建NONMEM群体模型。通过将第四步中获得的模型拟合到另外200个自助重复数据样本,评估群体药代动力学模型的性能。将获得的参数与模型稳定性步骤中获得的参数进行比较,并计算改进的预测误差,作为内部验证指标的预测准确性度量。血清肌酐倒数(RSC;f = 0.73)和HIV(f = 0.70)被GAM选为清除率(Cl)的预测因子。在未确定模型稳定性的情况下获得的群体药代动力学模型将RSC作为Cl的预测因子,但模型稳定性步骤中的最终模型将HIV和RSC都作为Cl的预测因子。用该模型拟合原始数据获得了最终的群体药代动力学参数;然而,HIV状态回归系数的95%置信区间包含零,表明无显著性。在回归稳定性步骤中,用另外200个自助重复数据样本获得的平均参数估计值在最终模型获得的值的15%以内。当没有测试数据集时,自助重采样程序通过反复将群体模型拟合到自助样本,对于评估群体模型的稳定性和性能很有用。